Stage 3 non-small cell lung cancer just got a major hope boost! A new trial found that adding immunotherapy (nivolumab) to chemo before and after surgery helped more patients stay cancer-free for longer—70% vs. 45% at one year. Plus, tumors shrank more and surgery was sometimes less intense. The catch? Not everyone could get to surgery, and side effects are real. Still, this could be a game-changer for some patients. Science is moving fast! #Health #BodyHealth #LungCancer